Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 704

Sort by

Sort Order Select

Journal Articles

TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS/AML for transplantation

Konstantinos Lontos, Rima M. Saliba, Rashmi Kanagal-Shamanna, Gonca Özcan, Jeremy Ramdial, George Chen, Tapan Kadia, Nicholas James Short, Naval G. Daver, Hagop Kantarjian, David Marin, Partow Kebriaei, Uday Popat, Richard Champlin, Elizabeth Shpall, Betül Oran

Blood Adv (2025) 9 (11): 2845–2854.

https://doi.org/10.1182/bloodadvances.2024014499

Published: 2025

Journal Articles

A cure for the kiss of death?

Jacob S. Appelbaum, Mary-Elizabeth Percival, Bart L. Scott

Blood Adv (2025) 9 (11): 2855–2856.

https://doi.org/10.1182/bloodadvances.2025015850

Published: 2025

Journal Articles

Long-term outcomes and quality of life with treosulfan-based conditioning in hematological malignancies

Rohtesh S. Mehta, Stephanie J. Lee, Ted Gooley, Laurel Thur, Ann Dahlberg, Colleen Delaney, Boglarka Gyurkocza, Phuong Vo, H. Joachim Deeg, Filippo Milano

Blood Adv (2025) 9 (11): 2691–2694.

https://doi.org/10.1182/bloodadvances.2024015392

Published: 2025

Journal Articles

BCL11A-deficient human erythropoiesis is impaired in vitro and after xenotransplantation into mice

Yoonjeong Jang, Ruopeng Feng, Lance E. Palmer, Thiyagaraj Mayuranathan, Yu Yao, Kalin Mayberry, Sheng Zhou, Jian Xu, Jeffrey M. Gossett, Guolian Kang, Yong Cheng, Jonathan S. Yen, Mitchell J. Weiss

Blood Adv (2025) 9 (11): 2722–2732.

https://doi.org/10.1182/bloodadvances.2024015574

Published: 2025

Includes: Supplemental data

Journal Articles

Phase 2 trial of cyclosporine-A, mycophenolate mofetil, and tocilizumab GVHD prophylaxis in cord blood transplantation

Blood Adv (2025) 9 (10): 2570–2584.

https://doi.org/10.1182/bloodadvances.2024014177

Published: 2025

Journal Articles

Tocilizumab prophylaxis in double cord blood transplantation

William R. Drobyski

Blood Adv (2025) 9 (10): 2585–2586.

https://doi.org/10.1182/bloodadvances.2024015785

Published: 2025

Journal Articles

Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation

Blood Adv (2025) 9 (10): 2553–2569.

https://doi.org/10.1182/bloodadvances.2024014879

Published: 2025

Includes: Supplemental data

Journal Articles

Impacts of donor age and HLA mismatch on HCT outcomes differ according to the donor CMV serostatus in unrelated allo-HCT

Shunto Kawamura, Daishi Nakagawa, Takashi Nagayama, Yuta Katayama, Noriko Doki, Wataru Takeda, Tetsuya Nishida, Ken-ichi Matsuoka, Takashi Ikeda, Hiroyuki Ohigashi, Masashi Sawa, Kentaro Fukushima, Junya Kanda, Kentaro Serizawa, Makoto Onizuka, Takahiro Fukuda, Yoshiko Atsuta, Yoshinobu Kanda, Hideki Nakasone

Blood Adv (2025) 9 (9): 2356–2365.

https://doi.org/10.1182/bloodadvances.2024014408

Published: 2025

Includes: Supplemental data

Journal Articles

GVHD in the era of checkpoint inhibition in Hodgkin lymphoma

Cecilia Anna Fidanza, Fabio Serpenti, Francesca Cavallaro, Kordelia Barbullushi, Nicolò Rampi, Francesca Gaia Rossi Dardanoni, Maria Goldaniga, Giorgia Natascia Saporiti, Francesco Passamonti

Blood Adv (2025) 9 (9): 2341–2343.

https://doi.org/10.1182/bloodadvances.2025015912

Published: 2025

Journal Articles

Improved survival with model-based dosing of antithymocyte globulin in pediatric hematopoietic cell transplantation

Rick Admiraal, Stefan Nierkens, Marc B. Bierings, Mirjam E. Belderbos, Alwin D. Huitema, Robbert G. M. Bredius, Yilin Jiang, Kevin J. Curran, Andromachi Scaradavou, Maria I. Cancio, Elizabeth Klein, Wouter J. Kollen, Dorine Bresters, Friso G. J. Calkoen, A. Birgitta Versluijs, C. Michel Zwaan, Jaap Jan Boelens, Caroline A. Lindemans

Blood Adv (2025) 9 (9): 2344–2353.

https://doi.org/10.1182/bloodadvances.2024014836

Published: 2025

Includes: Supplemental data

Journal Articles

Is transplant success linked to donor CMV serostatus?

Steven M. Devine

Blood Adv (2025) 9 (9): 2354–2355.

https://doi.org/10.1182/bloodadvances.2025015934

Published: 2025

Journal Articles

Impact of shared HLA determinants between patient and losing cord blood unit on relapse after double cord blood transplantation

Blood Adv bloodadvances.2025015938.

https://doi.org/10.1182/bloodadvances.2025015938

Published: 2025

Journal Articles

Interpretation of Response in BOS-the Definitions Remain Key

Kirsten M. Williams, Vibha N. Lama, Kenneth R. Cooke, Gregory A Yanik

Blood Adv bloodadvances.2025015948.

https://doi.org/10.1182/bloodadvances.2025015948

Published: 2025

Journal Articles

Belumosudil reduces oral chronic graft-versus-host disease tissue inflammation and fibrosis: a ROCKstar companion study

Blood Adv bloodadvances.2025016170.

https://doi.org/10.1182/bloodadvances.2025016170

Published: 2025

Includes: Supplemental data

Journal Articles

Impact of Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis in Patients 70 years and Older: An Update from BMT CTN 1703

Blood Adv bloodadvances.2025015964.

https://doi.org/10.1182/bloodadvances.2025015964

Published: 2025

Includes: Supplemental data

Journal Articles

Cutaneous dysbiosis characterizes the post–allogeneic hematopoietic stem cell transplantation period

Adela R. Cardones, Akintunde Emiola, Russell P. Hall, III, Anthony D. Sung, Jennifer Zhang, Amy J. Petty, Charles Puza, Lauren M. Bohannon, Amy T. Bush, Meagan V. Lew, Elizabeth Fleming, Yingai J. Jin, Krista Rowe Nichols, Vaibhav Jain, Simon G. Gregory, Keith M. Sullivan, Nelson J. Chao, Julia Oh

Blood Adv (2025) 9 (9): 2173–2182.

https://doi.org/10.1182/bloodadvances.2021004792

Published: 2025

Includes: Supplemental data

Journal Articles

Factors associated with early quality-of-life response to palliative care during hematopoietic cell transplantation

Richard Newcomb, Hermioni L. Amonoo, Alison R. Kavanaugh, Kristin C. Wharton, Michaela Rowland, James Fausto, Jason Webb, Vicki Jackson, Joseph A. Greer, Jennifer S. Temel, Porsha Lark, Dustin J. Rabideau, Karen O’Brien, Thomas W. LeBlanc, Stephanie J. Lee, Areej El-Jawahri

Blood Adv (2025) 9 (9): 2033–2043.

https://doi.org/10.1182/bloodadvances.2024014574

Published: 2025

Includes: Supplemental data

Journal Articles

Post transplant maintenance therapy with newly FDA-approved revumenib for high-risk KMT2Ar acute leukemia

Olayinka Okeleji, David McCall, Amber Gibson, Miriam B. Garcia, Cesar Nunez, Michael Roth, Jeremy Connors, Demetrios Petropoulos, Priti Tewari, Branko Cuglievan, Irtiza N. Sheikh

Blood Adv (2025) 9 (8): 1988–1990.

https://doi.org/10.1182/bloodadvances.2024015527

Published: 2025

Journal Articles

Delayed T cell recovery after hematopoietic cell transplantation is associated with decreased overall survival in adults

Miguel-Angel Perales, Marcie Riches, Naya He, Michael J. Martens, Roy F. Chemaly, Christopher E. Dandoy, Joshua A. Hill, Miguel A. Díaz, Shahrukh Hashmi, Susan E Prockop, Hillard M Lazarus, Amer M. Beitinjaneh, Gerhard C Hildebrandt, Jeff J. Auletta, Paul Szabolcs

Blood Adv bloodadvances.2024015288.

https://doi.org/10.1182/bloodadvances.2024015288

Published: 2025

Includes: Supplemental data

Journal Articles

Posttransplant cyclophosphamide as GVHD prophylaxis in patients receiving mismatched unrelated HCT: the PHYLOS trial

Blood Adv (2025) 9 (8): 1966–1975.

https://doi.org/10.1182/bloodadvances.2024015173

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS/AML for transplantation

A cure for the kiss of death?

Long-term outcomes and quality of life with treosulfan-based conditioning in hematological malignancies

BCL11A-deficient human erythropoiesis is impaired in vitro and after xenotransplantation into mice

Phase 2 trial of cyclosporine-A, mycophenolate mofetil, and tocilizumab GVHD prophylaxis in cord blood transplantation

Tocilizumab prophylaxis in double cord blood transplantation

Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation

Impacts of donor age and HLA mismatch on HCT outcomes differ according to the donor CMV serostatus in unrelated allo-HCT

GVHD in the era of checkpoint inhibition in Hodgkin lymphoma

Improved survival with model-based dosing of antithymocyte globulin in pediatric hematopoietic cell transplantation

Is transplant success linked to donor CMV serostatus?

Impact of shared HLA determinants between patient and losing cord blood unit on relapse after double cord blood transplantation

Interpretation of Response in BOS-the Definitions Remain Key

Belumosudil reduces oral chronic graft-versus-host disease tissue inflammation and fibrosis: a ROCKstar companion study

Impact of Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis in Patients 70 years and Older: An Update from BMT CTN 1703

Cutaneous dysbiosis characterizes the post–allogeneic hematopoietic stem cell transplantation period

Factors associated with early quality-of-life response to palliative care during hematopoietic cell transplantation

Post transplant maintenance therapy with newly FDA-approved revumenib for high-risk KMT2Ar acute leukemia

Delayed T cell recovery after hematopoietic cell transplantation is associated with decreased overall survival in adults

Posttransplant cyclophosphamide as GVHD prophylaxis in patients receiving mismatched unrelated HCT: the PHYLOS trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only